Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks

Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.

Original reporting
Published Aug 27, 2026, 6:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks — source image
Decision brief

The 30-second read

$EVHBullishHigh
01

Why it matters

Earnings beats and guidance raises for EVH and GDRX provide clear buying opportunities, while ASTH's miss may trigger profit‑taking. TNDM's in‑line results suggest limited upside.

02

Market read

The earnings releases provide fresh, material data that can drive short‑term trading decisions across the healthcare‑tech space.

03

What to watch

Potential regulatory changes in telehealth reimbursement could affect future profitability across the sector.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

The article compares Q2 earnings of four publicly traded healthcare‑technology companies, highlighting revenue growth, earnings beats/misses, and guidance updates.

Company-level read

Ticker impact

$EVHBullishHigh confidence
Context

Evolent Health reported Q2 revenue of $652.5M, a 46.9% YoY increase, beating analyst estimates and raising full-year guidance.

Expected impact

Potential continued rally, target +15% over next 2 weeks.

Evidence & confidence

Revenue beat, guidance raise, and 60% stock gain since release indicate strong market reaction.

$ASTHNeutralMedium confidence
Context

Astrana Health posted Q2 revenue of $972.5M, up 48.5% YoY but missed earnings estimates by 1.3% and gave slightly weaker guidance.

Expected impact

Possible short-term pullback of 5-8% as investors reassess earnings outlook.

Evidence & confidence

Revenue growth is strong, but earnings miss and weaker guidance could dampen sentiment.

$TNDMNeutralMedium confidence
Context

Tandem Diabetes reported Q2 revenue of $254.6M, up 5.8% YoY, in line with expectations, and met full-year guidance.

Expected impact

Sideways trading expected, +/-2% range.

Evidence & confidence

No surprise in earnings or guidance, so limited new catalyst.

$GDRXBullishHigh confidence
Context

GoodRx posted Q2 revenue of $200.4M, down 1.3% YoY but topped earnings expectations by 3.5% and raised full-year revenue and EBITDA guidance.

Expected impact

Potential upside of 8-12% as market digests stronger guidance.

Evidence & confidence

Guidance lift and earnings beat offset modest revenue decline, providing a bullish catalyst.

Market effects

Healthcare technology sector shows strong top‑line growth, but earnings quality varies across peers.

U.S. healthcare‑tech stocks may see divergent moves as investors reprice earnings beats versus misses.

Results highlight the broader trend of digital health adoption worldwide.

Counterpoint

Despite revenue growth, the earnings miss at Astrana Health could signal overvaluation; a short position may be justified.

Key entities

  • Evolent Health

    Provider of specialty care management services and technology solutions.

  • Astrana Health

    Technology‑powered healthcare platform focused on value‑based care.

  • Tandem Diabetes

    Developer of automated insulin delivery systems.

  • GoodRx

    Digital platform for prescription drug price comparison.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$TNDMMed

Why is Tandem Diabetes Care stock rallying today?

Tandem Diabetes Care (TNDM) stock rose 6.3% in pre-market trading after Stifel upgraded it to Buy with a $26 price target, citing an improving product pipeline and compelling valuation. The firm expects 50% upside and positive developments over the next year. TNDM recently received FDA clearance for its Tobi platform and reported strong Q3 2026 earnings, with revenue of $283.7 million, exceeding estimates. The stock trades below its 52-week high of $29.65.

$TNDMMedAI 8/10

Expanded Insulin Delivery Systems

Tandem Diabetes Care received Health Canada approval for its t:x2 insulin pump, expanding eligibility to adults with type 2 diabetes and pregnant individuals with type 1 diabetes. The pump is compatible with Abbott's FreeStyle Libre 3 Plus sensor, enabling minute-by-minute glucose readings. Clinical trials showed improved glucose management, including additional time in target range during pregnancy.